HALO
VENTE TOTALE: 61 626 titres (~6 335 132,80 $ US)
- Insiders
- Torley Helen, Connaughton Bernadette
- Total bought
- —
- Total sold
- $6,335,133
- Last activity
- 2026-08-19
- Last synced
-
2026-08-25 17:08:49
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-08-21
HALO benefits from a solid earnings catalyst — a Q2 beat with a raised 2026 outlook driven by ENHANZE royalties — but the composite fundamental picture is mixed, with strong cash flow offset by a severe leverage spike…
The first sentence of the analysis written for HALO on 2026-08-21 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 78.1% | 84.3% | 76.8% | 78.9% | 81.6% | |
| Ebit Margin | 34.7% | 56.7% | 44.3% | 40.3% | 57.8% | |
| Ebitda Margin | 41.0% | 64.7% | 54.5% | 47.8% | 58.4% | |
| Operating Profit Margin | 58.4% | 54.3% | 40.7% | 40.5% | 62.2% | |
| Pretax Profit Margin | 33.4% | 54.9% | 42.0% | 37.7% | 56.1% | |
| Continuous Operations Profit Margin | 22.7% | 43.7% | 34.0% | 30.6% | 90.8% | |
| Net Profit Margin | 22.7% | 43.7% | 34.0% | 30.6% | 90.8% | |
| Bottom Line Profit Margin | 22.7% | 43.7% | 34.0% | 30.6% | 90.8% | |
| Current Ratio | 4.660 | 7.803 | 6.635 | 5.650 | 7.907 | |
| Quick Ratio | 3.663 | 6.783 | 5.501 | 4.885 | 7.447 | |
| Solvency Ratio | 0.164 | 0.309 | 0.222 | 0.151 | 0.447 | |
| Cash Ratio | 0.756 | 0.833 | 1.052 | 1.791 | 1.013 | |
| Price To Earnings Ratio | 25.492 | 13.660 | 17.352 | 38.446 | 14.059 | |
| Price To Earnings Growth Ratio | -1.037 | 0.212 | 0.395 | -0.797 | 0.070 | |
| Forward Price To Earnings Growth Ratio | -1.037 | 0.212 | 0.395 | -0.797 | 0.070 | |
| Price To Earnings Diluted Ratio | 26.289 | 13.939 | 17.600 | 39.514 | 14.675 | |
| Price To Earnings Diluted Growth Ratio | -1.036 | 0.220 | 0.384 | -0.833 | 0.073 | |
| Price To Book Ratio | 165.224 | 16.666 | 58.181 | 45.857 | 28.714 | |
| Price To Sales Ratio | 5.775 | 5.972 | 5.880 | 11.796 | 12.757 | |
| Price To Free Cash Flow Ratio | 12.512 | 12.946 | 13.063 | 33.091 | 18.979 | |
| Price To Operating Cash Flow Ratio | 12.378 | 12.657 | 12.549 | 32.429 | 18.887 | |
| Debt To Assets Ratio | 0.848 | 0.730 | 0.865 | 0.818 | 0.794 | |
| Debt To Equity Ratio | 43.894 | 4.139 | 17.889 | 8.870 | 4.451 | |
| Debt To Capital Ratio | 0.978 | 0.805 | 0.947 | 0.899 | 0.817 | |
| Long Term Debt To Capital Ratio | 0.978 | 0.805 | 0.947 | 0.898 | 0.800 | |
| Financial Leverage Ratio | 51.734 | 5.672 | 20.681 | 10.845 | 5.608 | |
| Working Capital Turnover Ratio | 1.752 | 1.285 | 1.335 | 0.931 | 0.941 | |
| Operating Cash Flow Ratio | 3.679 | 3.444 | 3.454 | 1.836 | 2.556 | |
| Operating Cash Flow Sales Ratio | 0.467 | 0.472 | 0.469 | 0.364 | 0.675 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.989 | 0.978 | 0.961 | 0.980 | 0.995 | |
| Debt Service Coverage Ratio | 23.340 | 30.036 | 20.531 | 8.874 | 4.263 | |
| Interest Coverage Ratio | 45.034 | 30.477 | 17.992 | 15.786 | 36.660 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 18.007 | 3.349 | |
| Operating Cash Flow Coverage Ratio | 0.304 | 0.318 | 0.259 | 0.159 | 0.342 | |
| Capital Expenditure Coverage Ratio | 93.480 | 44.789 | 25.407 | 49.919 | 205.518 | |
| Dividend Paid And Capex Coverage Ratio | 93.480 | 44.789 | 25.407 | 49.919 | 205.518 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 17.580 | 11.353 | 13.844 | 28.710 | 24.758 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 78.1% | ▼-6.2% | ▼-1.8% |
| Ebit Margin | 34.7% | ▼-21.9% | ▼-12.0% |
| Ebitda Margin | 41.0% | ▼-23.6% | ▼-12.2% |
| Operating Profit Margin | 58.5% | ▲4.1% | ▲7.2% |
| Pretax Profit Margin | 33.4% | ▼-21.4% | ▼-11.4% |
| Continuous Operations Profit Margin | 22.7% | ▼-21.1% | ▼-21.7% |
| Net Profit Margin | 22.7% | ▼-21.1% | ▼-21.7% |
| Bottom Line Profit Margin | 22.7% | ▼-21.1% | ▼-21.7% |
| Current Ratio | 4.660 | ▼-3.143 | ▼-1.871 |
| Quick Ratio | 3.663 | ▼-3.119 | ▼-1.992 |
| Solvency Ratio | 0.164 | ▼-0.146 | ▼-0.095 |
| Cash Ratio | 0.756 | ▼-0.077 | ▼-0.333 |
| Price To Earnings Ratio | 25.492 | ▲11.832 | ▲3.690 |
| Price To Earnings Growth Ratio | -1.038 | ▼-1.250 | ▼-0.806 |
| Forward Price To Earnings Growth Ratio | -1.038 | ▼-1.250 | ▼-0.806 |
| Price To Earnings Diluted Ratio | 26.289 | ▲12.350 | ▲3.886 |
| Price To Earnings Diluted Growth Ratio | -1.036 | ▼-1.256 | ▼-0.798 |
| Price To Book Ratio | 165.224 | ▲148.557 | ▲102.295 |
| Price To Sales Ratio | 5.775 | ▼-0.197 | ▼-2.661 |
| Price To Free Cash Flow Ratio | 12.512 | ▼-0.434 | ▼-5.606 |
| Price To Operating Cash Flow Ratio | 12.378 | ▼-0.279 | ▼-5.402 |
| Debt To Assets Ratio | 0.849 | ▲0.119 | ▲0.037 |
| Debt To Equity Ratio | 43.894 | ▲39.755 | ▲28.045 |
| Debt To Capital Ratio | 0.978 | ▲0.172 | ▲0.089 |
| Long Term Debt To Capital Ratio | 0.978 | ▲0.172 | ▲0.092 |
| Financial Leverage Ratio | 51.734 | ▲46.062 | ▲32.826 |
| Working Capital Turnover Ratio | 1.752 | ▲0.467 | ▲0.503 |
| Operating Cash Flow Ratio | 3.679 | ▲0.235 | ▲0.685 |
| Operating Cash Flow Sales Ratio | 0.467 | ▼-0.005 | ▼-0.023 |
| Free Cash Flow Operating Cash Flow Ratio | 0.989 | ▲0.012 | ▲0.009 |
| Debt Service Coverage Ratio | 23.340 | ▼-6.696 | ▲5.931 |
| Interest Coverage Ratio | 45.034 | ▲14.558 | ▲15.844 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | ▼-4.271 |
| Operating Cash Flow Coverage Ratio | 0.304 | ▼-0.014 | ▲0.028 |
| Capital Expenditure Coverage Ratio | 93.480 | ▲48.691 | ▲9.658 |
| Dividend Paid And Capex Coverage Ratio | 93.480 | ▲48.691 | ▲9.658 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 17.580 | ▲6.227 | ▼-1.669 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $8.07B | $6.06B | $4.88B | $7.79B | $5.66B | |
| Enterprise value | $10.07B | $7.45B | $6.26B | $9.06B | $6.41B | |
| EV / Sales | 7.21x | 7.34x | 7.54x | 13.72x | 14.47x | |
| EV / Op. cash flow | 15.46x | 15.56x | 16.10x | 37.73x | 21.42x | |
| EV / Free cash flow | 15.63x | 15.91x | 16.76x | 38.50x | 21.52x | |
| EV / EBITDA | 17.58x | 11.35x | 13.84x | 28.71x | 24.76x | |
| Net debt / EBITDA | 3.50x | 2.12x | 3.06x | 4.03x | 2.93x | |
| Current ratio | 4.66x | 7.80x | 6.63x | 5.65x | 7.91x | |
| Income quality | 2.06x | 1.08x | 1.38x | 1.19x | 0.74x | |
| Graham number | $5 | $15 | $6 | $6 | $9 | |
| Graham net-net | -$16 | -$6 | -$8 | -$8 | -$1 | |
| Tax burden | 67.9% | 79.7% | 80.8% | 81.2% | 162.0% | |
| Interest burden | 96.3% | 96.9% | 94.9% | 93.6% | 97.1% | |
| Working capital | $648.1M | $946.2M | $633.9M | $608.2M | $809.1M | |
| Invested capital | $2.29B | $1.84B | $1.60B | $1.64B | $817.9M | |
| Return on assets | 12.5% | 21.5% | 16.2% | 11.0% | 36.5% | |
| Operating ROA | 35.6% | 29.0% | 18.9% | 18.2% | 32.8% | |
| Return on tangible assets | 32.9% | 35.7% | 33.4% | 22.8% | 36.5% | |
| Return on equity | 649.2% | 122.1% | 336.0% | 119.0% | 204.5% | |
| Return on invested capital | 23.6% | 22.8% | 16.8% | 12.6% | 25.6% | |
| Return on capital employed | 34.8% | 28.7% | 20.8% | 15.6% | 27.9% | |
| Earnings yield | 3.9% | 7.3% | 5.8% | 2.6% | 7.1% | |
| Free cash flow yield | 8.0% | 7.7% | 7.7% | 3.0% | 5.3% | |
| Capex / Op. cash flow | 1.1% | 2.2% | 3.9% | 2.0% | 0.5% | |
| Capex / Depreciation | 7.9% | 12.1% | 18.0% | 8.4% | 21.9% | |
| Capex / Sales | 0.5% | 1.1% | 1.8% | 0.7% | 0.3% | |
| SG&A / Sales | 13.8% | 15.2% | 18.0% | 21.7% | 11.4% | |
| R&D / Sales | 5.8% | 7.8% | 9.2% | 10.1% | 8.0% | |
| Stock comp / Sales | 3.7% | 4.3% | 4.4% | 3.7% | 4.7% | |
| Intangibles / Total assets | 61.8% | 39.7% | 51.3% | 51.9% | 0.0% | |
| Days sales outstanding | 115d | 111d | 103d | 128d | 75d | |
| Days payables outstanding | 25d | 23d | 22d | 46d | 7d | |
| Operating cycle | 326d | 436d | 345d | 390d | 317d | |
| Cash conversion cycle | 301d | 412d | 323d | 344d | 310d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+33.0%EV / Sales ▼-1.7%EV / EBITDA ▲+54.8%EV / Op. cash flow ▼-0.097Earnings yield ▼-0.034Graham number ▼-10.111
Profitability
Return on equity ▲+5.271Return on assets ▼-0.090Return on invested capital ▲+0.008Return on capital employed ▲+0.061Operating ROA ▲+0.065Income quality ▲+0.977Tax burden ▼-0.118
Efficiency
Days sales outstanding ▲+4.438Days payables outstanding ▲+1.509Operating cycle ▼-109.473Cash conversion cycle ▼-110.982Capex / Sales ▼-0.006R&D / Sales ▼-0.020
Balance-sheet strength
Current ratio ▼-3.143Net debt / EBITDA ▲+1.388Working capital ▼-298125000.000Invested capital ▲+452153000.000Intangibles / Total assets ▲+0.222
Change over 5 years
Valuation
Market cap ▲+42.6%EV / Sales ▼-50.1%EV / EBITDA ▼-29.0%EV / Op. cash flow ▼-5.956Earnings yield ▼-0.032Graham number ▼-4.575
Profitability
Return on equity ▲+4.447Return on assets ▼-0.239Return on invested capital ▼-0.020Return on capital employed ▲+0.068Operating ROA ▲+0.028Income quality ▲+1.313Tax burden ▼-0.942
Efficiency
Days sales outstanding ▲+40.421Days payables outstanding ▲+18.066Operating cycle ▲+9.624Cash conversion cycle ▼-8.441Capex / Sales ▲+0.002R&D / Sales ▼-0.022
Balance-sheet strength
Current ratio ▼-3.247Net debt / EBITDA ▲+0.579Working capital ▼-161025000.000Invested capital ▲+1474145000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2025-03-24 | Gilbert Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2024-09-09 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2023-07-12 | Daniel Goldman | Sale | $15,001 - $50,000 |
| 2022-12-06 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2020-10-22 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2020-10-19 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
Recent news
- 2026-08-24 NeoGenomics, Inc. (NEO) Hits Fresh High: Is There Still Room to Run? NeoGenomics (NEO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company''s fundamentals for clues.
- 2026-08-24 Halozyme Therapeutics: Running Through 2027 Halozyme Therapeutics shares have appreciated over 80% since my initial coverage and investment in 2024. My previous articles outlined a bullish investment thesis and detailed expectations for HALO''s performance in the current year. HALO''s stock performance has delivered significant returns, validating the earlier investment case and strategic positioning.
- 2026-08-22 Allworth Financial LP Acquires New Shares in Halozyme Therapeutics, Inc. $HALO Allworth Financial LP bought a new stake in Halozyme Therapeutics, Inc. (NASDAQ: HALO) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 37,664 shares of the biopharmaceutical company''s stock, valued at approximately $2,948,000. Several other institutional investors have also
- 2026-08-21 HALO Stock Rises 36% in a Month: Here''s What You Should Know Halozyme stock jumps 36% in a month as strong ENHANZE-driven royalties and recently raised 2026 guidance boost investor confidence.
- 2026-08-19 Add These 4 GARP Stocks to Your Portfolio to Receive Handsome Returns The GARP strategy helps investors gain exposure to stocks that have solid prospects and are trading at a discount. RL, AMP, HALO and NVDA are some such stocks.
- 2026-08-18 Halozyme Appoints Dannielle Appelhans to its Board of Directors SAN DIEGO, Aug. 18, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced the election of Dannielle Appelhans to its Board of Directors. Ms. Appelhans brings more than 20 years of executive leadership across the biotechnology and pharmaceutical industries, with deep expertise in operations, manufacturing, and supply chain management.
- 2026-08-18 Sagtec Officially Launches HALO AI and Secures US$3 Million Purchase Order for 1,500 AI Food-Serving Robots from Dubai Distributor Major Commercialization Milestone Expands Sagtec''s AI Robotics Platform into the Middle East and Establishes Initial Large-Scale Deployment Major Commercialization Milestone Expands Sagtec''s AI Robotics Platform into the Middle East and Establishes Initial Large-Scale Deployment
- 2026-08-13 Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why Halozyme Therapeutics (HALO) is well positioned to outperform the market, as it exhibits above-average growth in financials.
- 2026-08-13 Is Halozyme Therapeutics (HALO) Stock Outpacing Its Medical Peers This Year? Here is how Halozyme Therapeutics (HALO) and Brookdale Senior Living (BKD) have performed compared to their sector so far this year.
- 2026-08-07 Halozyme''s Q2 Earnings Beat Estimates, 2026 Outlook Raised, Stock Up HALO''s Q2 earnings and revenues surpass estimates, fueled by higher royalties and product sales. The company raises its 2026 outlook.